Data and Safety Monitoring The Data and Safety Monitoring Committee (DSMC) provides rigorous review of all industry and institutional protocols at the HCCC. More specifically, the primary duties of the DSMC are to: ? prospectively screen all patients entering HCCC investigator-initiated trials for trial-specified eligibility. The study coordinator delivers a completed eligibility checklist, with test results, to the safety officer, who verifies that the inclusion and exclusion criteria are met. Questions or concerns about eligibility are discussed with the DSMC chair and/or the Study Monitor. The safety officer then communicates DSMC approval, questions or concerns to the research team before the subject is enrolled in the trial. ? assess safety by reviewing all severe adverse events and ensure timely and appropriate reporting to oversight agencies (e.g. NCI, FDA, IRB) ? conduct audits of selected trials for data veracity, protocol adherence, and subject safety based on overall HCCC Data and Safety Monitoring Plan and the risk level of the study. The DSMC has the authority to close a clinical trial by contacting the IRB should safety issues warrant such closure.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-12
Application #
8381333
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-05-03
Budget End
2013-03-31
Support Year
12
Fiscal Year
2012
Total Cost
$82,317
Indirect Cost
$32,872
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Ghahramani, Grant K; Goetz, Kirsten E; Liu, Vincent (2018) Dermoscopic characterization of cutaneous lymphomas: a pilot survey. Int J Dermatol 57:339-343
Jorgensen, Jeffery B; Smith, Russell B; Coughlin, Andrew et al. (2018) Impact of PET/CT on Staging and Treatment of Advanced Head and Neck Squamous Cell Carcinoma. Otolaryngol Head Neck Surg :194599818794479
Jain, Rohit K; Snyders, Travis; Nandgoapal, Lakshminarayanan et al. (2018) Immunotherapy Advances in Urothelial Carcinoma. Curr Treat Options Oncol 19:79
Thompson, Carrie A; Yost, Kathleen J; Maurer, Matthew J et al. (2018) Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. Hematol Oncol 36:749-756
Brandt, Kristin E; Falls, Kelly C; Schoenfeld, Joshua D et al. (2018) Corrigendum to: Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells [Redox Biol. (2018) 82-87]. Redox Biol :
Ding, George X; Alaei, Parham; Curran, Bruce et al. (2018) Image guidance doses delivered during radiotherapy: Quantification, management, and reduction: Report of the AAPM Therapy Physics Committee Task Group 180. Med Phys 45:e84-e99
Wilkes, Justin G; O'Leary, Brianne R; Du, Juan et al. (2018) Pharmacologic ascorbate (P-AscH-) suppresses hypoxia-inducible Factor-1? (HIF-1?) in pancreatic adenocarcinoma. Clin Exp Metastasis 35:37-51
Sweeney, Sean K; Manzar, Gohar S; Zavazava, Nicholas et al. (2018) Tracking embryonic hematopoietic stem cells to the bone marrow: nanoparticle options to evaluate transplantation efficiency. Stem Cell Res Ther 9:204
Alexander, Matthew S; O'Leary, Brianne R; Wilkes, Justin G et al. (2018) Enhanced Pharmacological Ascorbate Oxidation Radiosensitizes Pancreatic Cancer. Radiat Res :
Gilbertson-White, Stephanie; Yeung, Chi W; Saeidzadeh, Seyedehtanaz et al. (2018) Engaging Stakeholders in the Development of an eHealth Intervention for Cancer Symptom Management for Rural Residents. J Rural Health :

Showing the most recent 10 out of 1080 publications